Finance

Lists
Why is 544222 down 2,48%?
Dive Deeper
544222:BOM
Akums Drugs and Pharmaceuticals Ltd
730,70 INR
-2,48%
(-18,60) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 544222...
Open
740,85 INR
High
749,30 INR
Low
729,40 INR
Mkt. cap
111,92 მლრ.
Avg. vol.
11,51 ათ.
Volume
5,90 ათ.
Dividend
0,14%
Quarterly dividend
0,25 INR
Ex-dividend date
3 ივლ. 2026
P/E ratio
38,36
52-wk high
839,25 INR
52-wk low
410,10 INR
EPS
19,05 INR
No. of employees
7 ათ.
Open
740,85 INR
High
749,30 INR
Low
729,40 INR
Mkt. cap
111,92 მლრ.
Avg. vol.
11,51 ათ.
Volume
5,90 ათ.
Dividend
0,14%
Quarterly dividend
0,25 INR
Ex-dividend date
3 ივლ. 2026
P/E ratio
38,36
52-wk high
839,25 INR
52-wk low
410,10 INR
EPS
19,05 INR
No. of employees
7 ათ.
News stories
From web sources and news partners
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7,34 ათ.
Founded2004
Headquarters-
SectorHealth care
Websiteakums.in
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
10,18 მლრდ.
11,60 მლრდ.
11,60 მლრდ.
11,67 მლრდ.
Cost of goods sold
5,93 მლრდ.
6,79 მლრდ.
7,37 მლრდ.
6,45 მლრდ.
Cost of revenue
5,93 მლრდ.
6,79 მლრდ.
7,37 მლრდ.
6,45 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 მლრდ.
1,89 მლრდ.
2,37 მლრდ.
2,01 მლრდ.
Operating expense
3,68 მლრდ.
3,74 მლრდ.
3,09 მლრდ.
3,88 მლრდ.
Total operating expenses
9,61 მლრდ.
10,52 მლრდ.
10,46 მლრდ.
10,33 მლრდ.
Operating income
566,12 მლნ.
1,07 მლრდ.
1,14 მლრდ.
1,34 მლრდ.
Other non operating income
323,65 მლნ.
343,28 მლნ.
-942,12 მლნ.
303,80 მლნ.
EBT including unusual items
656,73 მლნ.
995,66 მლნ.
1,21 მლრდ.
1,39 მლრდ.
EBT excluding unusual items
656,73 მლნ.
1,18 მლრდ.
1,19 მლრდ.
1,39 მლრდ.
Income tax expense
229,77 მლნ.
318,92 მლნ.
398,74 მლნ.
382,59 მლნ.
Effective tax rate
34,99%
32,03%
32,89%
27,48%
Other operating expenses
1,41 მლრდ.
1,45 მლრდ.
319,86 მლნ.
1,45 მლრდ.
Net income
407,83 მლნ.
663,17 მლნ.
846,13 მლნ.
1,00 მლრდ.
Net profit margin
4,01%
5,72%
7,29%
8,57%
Earnings per share
2,66
5,14
-
6,53
Interest and investment income
-
-
1,10 მლრდ.
-
Interest expense
-233,04 მლნ.
-237,42 მლნ.
-184,41 მლნ.
-247,56 მლნ.
Net interest expenses
-233,04 მლნ.
-237,42 მლნ.
912,36 მლნ.
-247,56 მლნ.
Depreciation and amortization charges
378,64 მლნ.
396,49 მლნ.
401,18 მლნ.
410,65 მლნ.
EBITDA
940,04 მლნ.
1,42 მლრდ.
1,49 მლრდ.
1,69 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები